The Role of FAS Receptor Methylation in Osteosarcoma Metastasis

Osteosarcoma is the most frequent primary malignant bone tumor with an annual incidence of about 400 cases in the United States. Osteosarcoma primarily metastasizes to the lungs, where FAS ligand (FASL) is constitutively expressed. The interaction of FASL and its cell surface receptor, FAS, triggers apoptosis in normal cells; however, this function is altered in cancer cells. DNA methylation has previously been explored as a mechanism for altering FAS expression, but no variability was identified in the CpG island (CGI) overlapping the promoter. Analysis of an expanded region, including CGI shores and shelves, revealed high variability in the methylation of certain CpG sites that correlated significantly with FAS mRNA expression in a negative manner. Bisulfite sequencing revealed additional CpG sites, which were highly methylated in the metastatic LM7 cell line but unmethylated in its parental non-metastatic SaOS-2 cell line. Treatment with the demethylating agent, 5-azacytidine, resulted in a loss of methylation in CpG sites located within the FAS promoter and restored FAS protein expression in LM7 cells, resulting in reduced migration. Orthotopic implantation of 5-azacytidine treated LM7 cells into severe combined immunodeficient mice led to decreased lung metastases. These results suggest that DNA methylation of CGI shore sites may regulate FAS expression and constitute a potential target for osteosarcoma therapy, utilizing demethylating agents currently approved for the treatment of other cancers.

[1]  T. Triche,et al.  Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma , 2022, International journal of molecular sciences.

[2]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Gangning Liang,et al.  Gene body methylation can alter gene expression and is a therapeutic target in cancer. , 2014, Cancer cell.

[4]  N. Yamamoto,et al.  Prognostic Value of Histological Response to Chemotherapy in Osteosarcoma Patients Receiving Tumor-Bearing Frozen Autograft , 2013, PloS one.

[5]  P. Laird,et al.  Low-level processing of Illumina Infinium DNA Methylation BeadArrays , 2013, Nucleic acids research.

[6]  R. Weksberg,et al.  Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.

[7]  Francesco Marabita,et al.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data , 2012, Bioinform..

[8]  J W Gray,et al.  CpG island shore methylation regulates caveolin-1 expression in breast cancer , 2012, Oncogene.

[9]  Matthew T. Maurano,et al.  Widespread plasticity in CTCF occupancy linked to DNA methylation , 2012, Genome research.

[10]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[11]  W. Pickl,et al.  5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. , 2012, Blood.

[12]  I. King Jordan,et al.  On the presence and role of human gene-body DNA methylation , 2012, Oncotarget.

[13]  E. Kleinerman,et al.  miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. , 2012, Cancer research.

[14]  P. Krammer,et al.  Regulation of CD95/Fas signaling at the DISC , 2011, Cell Death and Differentiation.

[15]  G. Wood,et al.  Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. , 2011, Archives of dermatology.

[16]  F. Lyko,et al.  Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines , 2011, PloS one.

[17]  R. Gorlick,et al.  Osteosarcoma: a review of diagnosis, management, and treatment strategies. , 2010, Clinical advances in hematology & oncology : H&O.

[18]  S. Whittaker,et al.  Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation. , 2010, The Journal of investigative dermatology.

[19]  Michael Rehli,et al.  General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. , 2010, Cancer research.

[20]  Martin J Aryee,et al.  Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts , 2009, Nature Genetics.

[21]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[22]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[23]  Rafael A. Irizarry,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[24]  S. Ropero,et al.  A microRNA DNA methylation signature for human cancer metastasis , 2008, Proceedings of the National Academy of Sciences.

[25]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[26]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[27]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Pipper,et al.  [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.

[29]  A. Huvos,et al.  Treatment of osteosarcoma at first recurrence after contemporary therapy , 2005, Cancer.

[30]  E. Kleinerman,et al.  Fas Expression in Lung Metastasis From Osteosarcoma Patients , 2005, Journal of pediatric hematology/oncology.

[31]  E. Kleinerman,et al.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Kleinerman,et al.  Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells , 2004, Clinical Cancer Research.

[33]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[34]  R. Stahel,et al.  Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation , 2003, Cell Death and Differentiation.

[35]  L. Berczi,et al.  Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma , 2003, Cell Death and Differentiation.

[36]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[37]  E. Kleinerman,et al.  Fas expression inversely correlates with metastatic potential in osteosarcoma cells. , 2002, Oncology reports.

[38]  Peter A. Jones,et al.  Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[39]  W. Schulz,et al.  Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo‐1) gene promoter at rel/nuclear factor κB sites in prostatic carcinoma , 2001, Molecular carcinogenesis.

[40]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[42]  S. Ferrari,et al.  Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Souhami,et al.  Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup , 1997, The Lancet.

[44]  A. Craft,et al.  A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Prydz,et al.  CpG islands as gene markers in the human genome. , 1992, Genomics.

[46]  R. Mendes.  R: The R Project for Statistical Computing , 2016 .

[47]  E. Kleinerman,et al.  Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation. , 2009, Oncology research.

[48]  G. Ottaviani,et al.  The epidemiology of osteosarcoma. , 2009, Cancer treatment and research.

[49]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[50]  E. Kleinerman,et al.  A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies , 2004, Clinical & Experimental Metastasis.

[51]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .